Journal
TOXICON
Volume 39, Issue 8, Pages 1173-1181Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/S0041-0101(00)00254-3
Keywords
Bothrops asper venom; hyperalgesia; bradykinin; leukotrienes
Categories
Ask authors/readers for more resources
The ability of Bothrops asper snake venom to cause hyperalgesia was investigated in rats, using the paw pressure test. Intraplantar injection of the venom (5-15 mug/paw) caused a dose and time-related hyperalgesia. which peaked 2 h after venom injection. Bothrops asper venom-induced hyperalgesia was blocked by the bradykinin B-2 receptor antagonist HOE 140 and attenuated by dexamethasone, an inhibitor of phospholipase A(2). Inhibition of the lipoxygenase pathway by NDGA abrogated the algogenic phenomenon. The hyperalgesic response was not modified by pretreatment with indomethacin, an inhibitor of the cyclo-oxygenase pathway, by meloxicam, an inhibitor of the type 2 cyclo-oxygenase pathway, by the PAF receptor antagonist BN52021 or by anti-TNF-alpha or anti-interleukin 1 antibodies. Intraplantar injection of the venom also caused an oedematogenic response which was not modified by any of these pharmacological treatments. These results suggest that hyperalgesia induced by Bothrops asper venom is, at least partially, mediated by bradykinin, phospholipase A(2) activity and leukotrienes. Distinct mechanisms: are involved in the development of hyperalgesia and oedema induced by the venom. (C) 2001 Elsevier Science Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available